In fact, a higher rate of malignancies was found among IBD patients treated with the combination of TNF-α inhibitors and thiopurine (azathioprine or 6-mercaptopurine) compared to those treated without thiopurine (standardized incidence ratios of 6.0 vs. 2.5, respectively) [115]. Here, TNF is linked to inflammatory bowel disease.